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Abstract
This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or
anti-T lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) after allogeneic hematopoietic
stem cell transplantation (HSCT). A comprehensive review of articles released up to October, 2018 was performed as a
source of scientific evidence. Fourteen clinically relevant key questions to the domains indication, administration, and post-
transplant management were developed and recommendations were produced using the Delphi technique involving a Panel
of 14 experts. ATG/ATLG was strongly recommended as part of myeloablative conditioning regimen prior to matched or
mismatched unrelated bone marrow or peripheral blood allogeneic HSCT in malignant diseases to prevent severe acute and
chronic GvHD. ATG/ATLG was also recommended prior to HLA-identical sibling peripheral HSCT with good but lesser
bulk of evidence. In reduced intensity or nonmyeloablative conditioning regimens, ATG/ATLG was deemed appropriate to
reduce the incidence of acute and chronic GvHD, but a higher risk of relapse should be taken into account.
Recommendations regarding dose, application, and premedication were also provided as well as post-transplant infectious
prophylaxis and vaccination. Overall, these recommendations can be used for a proper and safe application of polyclonal
ATG/ATLG to prevent GvHD after allogeneic HSCT.
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Introduction
Graft-versus-host disease (GvHD) is one of the most
important factor limiting the success of allogeneic hema-
topoietic stem cell transplantation (HSCT) [1, 2] because it
negatively affects both the duration and quality of life of
patients after transplant [3].
The most widely used strategy for GVHD prevention, at
least in Europe [4], is the addition of rabbit antilymphocyte
serum to the standard prophylaxis with a calcineurin inhi-
bitor and either methotrexate or mycophenolate mofetil.
There are several formulations of polyclonal antilympho-
cyte sera available in different countries, generated in ani-
mals (rabbits, horses, and pigs) by inoculation of human
thymocytes or human cell line. Available rabbit polyclonal
antilymphocyte sera are the antithymocyte globulin (ATG)
(Sanofi Genzyme, Cambridge MA), derived from rabbit
vaccination with human thymocytes, and the anti-T-
lymphocyte globulin (ATLG) (Neovii, Rapperswil, Swit-
zerland, formerly ATG Fresenius®), derived from the
human Jurkat T-cell line. Horse ATG (hATG, ATGAM®,
Pfizer Inc NY, US) is used as first-line therapy of
moderate–severe aplastic anemia [5] as well as GvHD
prophylaxis [6]. Finally, porcine ATG is also used for the
treatment of severe aplastic anemia especially in China and
India [7] and, less frequently, in the setting of HSCT [8].
Here we restrict the consensus to rabbit sera because of their
prevalent use as drugs for GvHD prevention.
Since rabbit polyclonal serum reacts against host and
donor lymphocytes, the expected effects are both the
reduction of the risk of GvHD and the prevention of graft
failure.
Data regarding the use of rabbit polyclonal serum in
patients undergoing allogeneic HSCT indicate that both
ATG and ATLG significantly reduce the incidence of
GvHD but their administration is associated with delayed
immune reconstitution [9, 10]. As a consequence, they lead
potentially to an increased risk of infections and of leukemia
relapse. Despite the most recent meta-analysis did not show
any significant benefit of ATG/ATLG on post-transplant
survival [11], data from different studies are still discordant
because of different formulations, doses, and timing used as
well as the heterogeneity of the studied populations, the
hematopoietic stem cell sources, and the intensity of the
conditioning regimens.
The aim of this collaborative initiative is to provide
consensus-based recommendations for indication and
administration of ATG/ATLG as part of the conditioning
regimen prior to allogeneic HSCT, as well as for post-
transplant management. These recommendations should be
used as practical guidelines for ATG/ATLG therapy and in
helping to address the scientific questions for clinical trials
in the domain of indications and administration in allo-
geneic HSCT.
The consensus process
Two chairpersons (NK and FB) appointed a panel of 14
physicians (hereafter referred to as the Panel), selected for
their expertize in research and clinical practice of allogeneic
HSCT. A clinician with expertize in clinical epidemiology
(GB) assured the methodological correctness of the process
(Delphi technique [12]). The key questions were ranked
according to their priority votes, with the 14 that ranked
highest forming the set of questions in the present recom-
mendations (Table 1). Searches of the literature in English
were performed using MEDLINE, EMBASE, and PubMed
database (up to October, 2018). Three panelists drafted
statements that addressed the identified key questions, and
remaining panelists scored their agreement with those
statements and provided suggestions for rephrasing.
Results
Domain 1: indications for ATG/ATLG therapy
Recommendations
ATG/ATLG is recommended as part of chemotherapy- or
total body irradiation (TBI)-based myeloablative con-
ditioning (MAC) regimen prior to matched or mismatched
unrelated bone marrow (BM) or peripheral blood (PB)
allogeneic HSCT in malignant diseases to prevent severe
acute and chronic GvHD.
The Panel also agreed that ATG/ATLG should be
recommended prior to HLA-identical sibling PB allogeneic
HSCT, even though the evidence of efficacy is based only on
one randomized trial, compared with four trials in unre-
lated allogeneic HSCT.
In reduced intensity conditioning (RIC) or non-
myeloablative (NMA) conditioning regimens, the use of
ATG/ATLG is appropriate to reduce the incidence of acute
and chronic GvHD, but a higher risk of relapse should be
taken into account. The Panel agreed that the use of ATG/
ATLG in this setting should be considered in relation to the
intensity of conditioning and based on risk of disease
relapse.
The Panel did not reach a consensus on the use of ATG/
ATLG as GvHD or graft failure prophylaxis in T-cell
replete haploidentical allogeneic HSCT when post-
transplant cyclophosphamide (PTCy) is used. Almost all
non-PTCy regimens include ATG/ATLG therapy, so no
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comparative evidence can be derived and these regimens
should be followed as originally reported.
The Panel did not reach a consensus about the appro-
priateness of use of ATG/ATLG in cord blood HSCT.
ATG/ATLG is recommended as GvHD and graft failure
prophylaxis in nonmalignant diseases such as aplastic
anemia where no graft-versus-leukemia (GVL) effect is
required.
The Panel agreed that the indication for ATG/ATLG
should not depend on patient age, although the tolerability
of ATG/ATLG in older patients is lower.
Summary of evidence
We analyzed five randomized clinical trials (RCTs) evalu-
ating the use of ATG/ATLG in allogeneic HSCT from
unrelated (four trials) and related donors (one trial) [13–17].
In the trials with unrelated donors [13–16] the difference in
incidence of cGvHD between ATG/ATLG and no ATG/
ATLG arms ranged from 11 to 28%, while for acute GvHD
(aGVHD), considering the appropriate doses of the drug, it
ranged from 15 to 42%. In the study [17] focused on mat-
ched related donors, both the incidence and severity of
cGVHD decreased with the addition of ATLG.
All the four recent meta-analyses on ATG/ATLG
[11, 18–20] found a significant reduction of both cGvHD
and aGvHD, without any differences in OS and non-relapse
mortality (NRM), but one reported a higher risk of relapse
[11]. There were discrepancies among meta-analyses in
results on infections and relapse. In one [16] of the RCTs an
increase in relapse after ATLG was reported, particularly in
patients receiving a TBI-based conditioning regimen. On the
contrary, in a previous trial using the same doses of ATLG
(60mg/kg), no significant increase in relapse was seen [14].
Data from the meta-analyses did not allow the assessment
of the impact of RIC on the ATG/ATLG effect on GvHD
and risk of relapse. In fact, of the five [13–17] only one [17]
included also RIC transplants. Retrospective or non-
randomized studies have reported conflicting results on the
impact of ATG/ATLG in the setting of RIC transplants. In
particular, a higher dose of ATG/ATLG have been asso-
ciated with a higher risk of relapse thus leading to a
decreased disease-free survival (DFS) [21–24], especially
for advanced diseases. On the contrary, in a study of the
European Society for Blood and Marrow Transplantation
(EBMT) [25] assessing the outcome of patients with acute
myeloid leukemia (AML) and undergoing PB transplanta-
tion from HLA-identical siblings after a RIC in first com-
plete remission, the use of ATG was not significantly
associated with a higher risk of relapse; the outcomes of
NRM, leukemia-free survival, and OS were not significantly
associated with the use of ATG. Patients with advanced or
active disease were included only in some of the RCTs
[13–15]: this condition was generally found to be a sig-
nificant prognostic factor for relapse and for survival, but not
related to ATG/ATLG administration. The only available
Table 1 List of key questions.
Domain 1—Indications on use of ATG/ATLG
1 For which donor type, stem cell source, and type of conditioning of allogeneic HSCT is ATG/ATLG
administration indicated, contra indicated, or uncertain?
2 For which type of disease and phase of disease is ATG/ATLG administration during allogeneic HSCT
conditioning indicated, contra indicated or uncertain?
3 Are the indications of ATG/ATLG administration during allogeneic HSCT conditioning different
according to patient’s age and for pediatric and adult patients?
Domain 2—ATG/ATLG administration protocol
1 How should side effects of ATG/ATLG administration (such as systemic inflammation response
syndrome—SIRS) be prevented?
2 Which is the recommended schedule (timing and doses) of ATG/ATLG administration during
myeloablative, reduced intensity, and nonmyeloablative conditioning regimens?
3 What are the factors affecting the choice of the type and the brand of ATG/ATLG?
4 Should doses, schedule, and brand of ATG/ATLG administration differ for second transplants?
5 What is the recommended action in case of severe allergic reaction after first dose of ATG/ATLG?
6 Should the administration of ATG/ATLG be modified in case of suspected infection?
Domain 3—Post-transplant management in patients who received ATG/ATLG administration
1 What post-transplant infection prophylaxis is recommended after ATG/ATLG administration?
2 What post-transplant vaccination is recommended after ATG/ATLG administration?
3 Should DLI indication and dose be modified for patients who received ATG/ATLG?
4 Is universal prophylaxis or monitoring/preemptive treatment of post-transplant lymphoproliferative
disease appropriate in patients who received ATG/ATLG?
HSCT hematopoietic stem cell transplantation, ATG antithymocyte globulin, ATLG anti-T-lymphocyte
globulin.
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subgroup analysis [26], focused on relapse risk and the use
of ATLG in patients transplanted in the advanced phase,
showed a non-significant interaction between disease phase
and ATLG treatment in the setting of unrelated transplants.
In T-cell replete haploidentical HSCTs, ATG at higher
doses can be used as GvHD prophylaxis [27–29], but no
comparisons with different GvHD prophylaxis regimens are
available. In T-cell deplete haploidentical HSCT, ATG was
combined with TCR-αβ T-cell depletion to reduce both the
risk of graft failure and GVHD [30, 31]; with a TCR-α/β
depleted graft, a negative effect of ATG given close to
transplantation is expected since it may reduce the GvL
effect played by NK cells and gamma/delta T cells.
In cord blood HSCT, the addition of ATG/ATLG
resulted in a lower survival rate [32–35], although there is a
suggestion that results could be improved with earlier tim-
ing and/or lower doses of ATG [36, 37].
Specifically, in the pediatric setting, lower doses of
ATLG resulted in comparable prevention of GvHD as
higher ATLG doses but with a significant survival benefit
because of lower viral reactivation rate [38].
Finally, in non-malignant diseases, the role of ATG/
ATLG is easier to promote because GvHD should be
completely abrogated and an effective prevention of graft
failure is also required. Although not yet confirmed in the
context of RCTs, which failed in the past to demonstrate an
advantage using ATG [39], a recent report from the EBMT
Severe Aplastic Anemia Working Party, with large numbers
of patients, confirms the beneficial role of in vivo T-cell
depletion with ATG or Alemtuzumab, which was associated
with a significant survival benefit [40, 41].
Domain 2—ATG/ATLG administration protocol
Recommendations
In order to mitigate infusion reactions of ATG/ATLG, pre-
medication with steroids and antihistamine, or acet-
aminophen and a long-lasting infusion (≥12 h) in a central
high flow catheter are highly recommended.
The performance of skin tests before infusion to antici-
pate severe allergic reactions is not recommended.
In the event of reactions, it is suggested to temporarily
discontinue ATG/ATLG infusion, to strengthen the pre-
medication (higher doses of steroids, antihistamine, or
acetaminophen) and to increase the time of infusion, given
that patients should be carefully (or intensively) monitored.
In the very rare event of severe reactions (e.g., cytokine
release syndrome grade 4) a permanent discontinuation is
justified.
Reduction of ATG/ATLG dose for a suspected infection
occurring during the conditioning time should be based on
an individual patients’ case.
Recommended doses during MAC are 30 mg/kg and
60 mg/kg of ATLG for sibling and unrelated transplants,
respectively, from days −3 to −1 and 4.5–7.5 mg/kg for
ATG. For children, ATLG dosing at 15 mg/kg is as effective
as 30 mg/kg and has been demonstrated to be associated
with better event-free survival.
In the absence of prospective controlled studies on ATG/
ATLG in the setting of RIC and NMA transplants, no
recommendation on doses can be given.
No factors affecting the choice of the brand of rabbit
polyclonal globulin can be advised. The choice should be
preferably based on center experience.
The doses of ATG/ATLG should be calculated according
to body weight, although a recent study suggests that
optimal ATG/ATLG exposure may be improved when based
on the absolute number of lymphocytes (ALC).
Second transplants should be carried out with similar
doses of both ATG/ATLG as first transplants.
Summary of evidence
ATLG/ATG administration can be complicated by several
infusion reactions such as fever, chills, erythema, dyspnea,
oxygen desaturation, nausea/vomiting, diarrhea, abdominal
pain, hyperkalemia, tachycardia hypotension or hyperten-
sion, malaise, rash, urticaria, headache, arthralgia, myalgia,
hepatic cytolysis, and hypotension (level of up to severe),
that can be even unresponsive to conventional vasopressors
or, although rarely, systemic anaphylaxis. Most symptoms
can be attributed to the cytokine release syndrome (CRS)
and are reversible. CRS and other forms of infusion reac-
tions cannot be anticipated (e.g., by epicutaneous or intra-
dermal test). Serum sickness can develop after 5–15 days
and it generally responds well to steroid treatment [42–47].
Dose and timing of administration of ATLG and ATG
varies substantially among transplant centers. For ATLG the
total dose varies from total doses of 15–60 mg/kg; conven-
tional timing is generally from days −3 to −1 but also from
days −6 to −2 or −4 to −2 are reported. The ATG dose
varies from 4.5 to 7.5 mg/kg, with a schedule of adminis-
tration from days −3 to −1, or −2 to +1, and −4 to −2. In
the real life, doses of ATG/ATLG are different from those
used in clinical trials, as demonstrated by single-center
experiences and nonrandomized studies [48]. In the rando-
mized setting, three studies compared two doses of ATG/
ATLG: Bacigalupo et al. [13] employed two different doses
of ATG (15mg/kg or 7.5 mg/kg) in two separate rando-
mized trials with MAC conditioning in BM transplantation
from unrelated donors: rates of aGvHD appeared worse
(69%) with the lower dose as compared with the higher
(37%). However, the higher dose was associated with more
frequent serious infections. This trial was conducted before
high resolution HLA typing was available and GvHD may
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have been more severe. In the pediatric setting [38], a lower
dose of 15 mg/kg (experimental arm) of ATLG given to
children suffering from high risk acute leukemia and
undergoing unrelated transplants appears to be beneficial as
compared to 30 mg/kg (control arm) in terms of GVHD
prevention, while the event-free survival was superior in the
experimental arm because of the lower incidence of viral
infections. No significant difference between two different
doses of ATG (6 mg/kg vs. 10 mg/kg) in a RCT focused on
T-replete haploidentical [27] has been shown, in terms of
DFS, but higher doses were associated with an increased
incidence of Epstein–Barr virus (EBV) reactivation (25.3%
vs. 9.6%). Of note in all the three studies [13, 27, 38] higher
doses were always associated with higher infectious com-
plications but not with recurrence of the original disease,
with the exception of one study [13], which used very high
doses of ATG (15mg/kg).
A non-randomized comparison between 60 mg/kg vs.
30 mg/kg of ATLG [49], in patients with hematological
malignancies receiving a MAC regimen, showed that higher
doses were associated with an inferior outcome because of
greater fatal infections, while aGvHD, cGvHD, and relapse
were similar in the two groups. Binkert et al. [50] reported a
significant reduction of viral infections, cGvHD, NRM, and
increased OS after 35 mg/kg of ATLG in comparison with a
higher standard dose (60 mg/kg) and no ATLG, in the set-
ting of related and unrelated transplants. Retrospective
analyses reported a significant decrease of cGvHD and less
commonly aGVHD even with very low doses of ATLG
(15–30 mg/kg) in several series of patients transplanted after
MAC regimen, mainly with PBSC, both from matched
related and unrelated donors [51–54].
Regarding ATG, Ravinet et al. [55] reported that the
addition of ATG after a MAC regimen in patients with
acute leukemia and MDS transplanted from a well-matched
unrelated donor (10/10) was found to significantly reduce
aGvHD and cGvHD, and improve graft-versus-host dis-
ease-free, relapse-free survival only after PBSC but not after
BM transplantation. Survival, relapse, or NRM were not
affected by ATG administration.
Ratanatharathorn et al. [56] reported significantly lower
NRM, cGvHD incidence, and severity in patients receiving
4.5 mg/kg of ATG retrospectively compared with those who
did not receive ATG, independently from the intensity of
the conditioning regimen. The problem of dosage is parti-
cularly unsolved in the context of RIC transplants where the
balance between the intensity of conditioning regimen and
GVL–GvHD risk is sensitive [57]. For this reason, in the
absence of a focused clinical trial, the Panel agreed to take a
dose reduction of ATG/ATLG into consideration. Devillier
et al. [58] reported favorable outcomes (GvHD prevention,
no relapse increase) using ATG at 5 mg/kg in patients with
AML and MDS receiving PBSC from both a matched
related donor and unrelated after a RIC regimen [59]. The
EBMT reported a nonsignificant increase of relapse when
ATG dose was <6 mg/kg in patients that had a matched
related donor [60]. Currently used doses of ATG/ATLG are
calculated according to body weight [13–17]. Calculating
the ATG/ATLG dose according to cellular target, such as
ALC before infusion of the first dose [61, 62], which has
been shown to provide optimal drug exposure and then to
maximize the benefit (GvHD decrease) over the risks
(increase in relapse and infection). This concept has been
further validated by a post hoc analysis of a RCT [16],
where those patients with a lower ALC (<0.1 × 109/L) at the
time of first ATLG infusion, the progression free and OS
was inferior in comparison to the placebo arm and that a
TBI-based regimen was correlated with a lower ALC, thus
increasing the unfavorable effects of ATG.
Domain 3—posttransplant management in patients
who received ATG/ATLG
Recommendations
Post-transplant infection prophylaxis or preemptive therapy
for patients receiving ATG/ATLG should be similar to that
usually recommended after allogeneic HSCT (against
herpes simplex virus (HSV), varicella-zoster virus (VZV),
cytomegalovirus, pneumocystis jiroveci, toxoplasma gondii,
pneumococcus, and fungi).
Post-transplant vaccination schedule for patients
receiving ATLG or ATG should be similar to that commonly
recommended after allogeneic HSCT.
Donor lymphocyte infusion indication and dose should
not be modified in patients receiving ATG/ATLG.
Summary of evidence
The spectrum of antigens recognized by ATG/ATLG is
wide and includes antibody specificities against T, B lym-
phocytes, antigen presenting cells, monocytes, and more
generally inflammatory cells leading to a variety of
mechanisms of action [44, 63–67]. Compared with patients
not receiving ATG/ATLG, those treated with ATG/ATLG
show slower reconstitution of CD4+ and CD8+ T cells in
the PB for at least 1 year after transplantation, in particular
in terms of naive and memory CD4+ T cells [8, 9, 50], less
importantly of CD8+ cells [14], while the effects on B
lympocytes and natural killer cells are still controversial
[9, 10, 16, 50].
Impaired T cell reconstitution after allogeneic HSCT is
associated with worse survival [68] as well as a higher
risk of opportunistic viral reactivations and infections,
intracellular bacteria, and fungal infections [69]. In addi-
tion to antiinfection prophylaxis [70], patients receiving
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allogeneic HSCT needed to be vaccinated with attenuated
vaccines [71].
The association between in vivo T-cell depletion with
ATG/ATLG and increased risks of CMV and EBV reacti-
vation is still controversial mainly because different doses
and settings jeopardize the net final effect. From the point of
view of mechanism of action, ATG/ATLG administration,
causing a delayed immune reconstitution, increases the risk
of infections [72, 73]; however not all the studies show an
increase in viral infections because of the current dose
variation. Both prospective [13–17, 38] and retrospective
data [47] confirmed an overall trend toward an increased
infection risk only in patients treated with higher doses,
while the risk of CMV and EBV reactivation was increased
in one meta-analysis [18] but not in another one [19]. It has
been suggested that the risk of EBV/PTLD increases in
patients with high serum levels of active ATG at the time of
transplantation [62], which is consistent with the impact of
ATG exposure analyzed by pharmacokinetics on CD4+
immune reconstitution [61, 68]. EBV reactivation can be
prevented or preemptively treated with rituximab [74].
Prevention of EBV reactivation my be considered particu-
larly in patients with SAA, because of the combination of
risk factors [75].
Discussion
Clinical trials have documented the efficacy of ATG/ATLG
to prevent acute and cGvHD after allogeneic HSCT for
malignant and non-malignant diseases. However, a number
of practical issues regarding the use of ATG/ATLG are still
unsolved, due to the interplay of a large number of con-
founding variables impacting the outcome after HSCT,
making the interpretation of data on the efficacy of ATG/
ATLG as GvHD prophylaxis troublesome. In this paper,
experts in the field of allogeneic HSCT aimed to use a
consensus method, provide recommendations regarding the
indication and management of ATG/ATLG before allo-
geneic HSCT as well as posttransplant monitoring.
ATG/ATLG is now frequently used as GvHD prevention
in Europe [4] with the highest evidence derived from RCTs,
numerous non-RCTs, and meta-analyses.
ATG/ATLG effectively prevents GvHD, in particular
cGvHD, after transplants from almost any donor types; the
strongest evidence of efficacy comes from studies on
transplants with unrelated and matched related donors
(Table 2). Consequently, in these settings the Panel reached
a high level of agreement. The increase in infection risk was
overall less than expected and if at all, was limited to the use
of higher doses of ATG/ATLG. Similarly, a dose-dependent
relationship can be found with the speed of immune
reconstitution. Relapse is increased only in one [16] of the
randomized studies [12–15, 17, 38], in a particular subset of
patients receiving a TBI-based conditioning regimen, but a
retrospective analysis of the Acute Leukemia Working
Party of the EBMT [76] did not confirm this finding.
Advanced phase at transplant is a well-recognized risk
factor for poorer survival, in particular for relapse, inde-
pendently of ATLG infusion [26]. ATG/ATLG, in reducing
GvHD, could decrease the protective effect of GvHD on
relapse, in particular of cGvHD [77]; in this setting, due to
Table 2 Final recommendations.
Conditioning regimen Stem cell source Donor Recommendation Agreement
among experts
MALIGNANT DISEASES
Myeloablative Bone marrow/
peripheral blood
Unrelated Recommended Full
Myeloablative Peripheral blood HLA-identical sibling Recommended Partial
RIC/NMA Bone marrow/
peripheral blood
HLA-identical sibling/matched
or mismatched unrelated
Partially recommended Partial
Any conditioning plus post-transplant
cyclophosphamide
Bone marrow/
peripheral blood
Haploidentical Undecidable Full
Any conditioning without post-
transplant cyclophosphamide)
Bone marrow/
peripheral blood
Haploidentical Advised to follow the
conditioning published
protocols
Full
Any conditioning Cord blood
transplant
Cord blood Undecidable Full
NON-MALIGNANT DISEASES
Any conditioning Any stem cell
source
Recommended Full
RIC reduced intensity conditioning, NMA nonmyeloablative conditioning.
1098 F. Bonifazi et al.
the higher risk of relapse a potential further increase in
disease recurrence, by means of ATLG infusion, cannot be
completely excluded. Accordingly in the real life we
observe a clear tendency to use doses lower than those used
in the RCTs [78].
Lack of relevant clinical trials specifically addressing
critical questions on the indication and use of ATG/ATLG
has been highlighted by the experts of this project. A major
issue was ATG/ATLG dose optimization. Up to now, no
dose finding studies have been performed; moreover, the
two formulations (ATLG and ATG) show different pattern
of antibody specificity [79], hence results obtained with one
globulin cannot be applied to the other one. One possible
solution could be to use ATG/ATLG according to phar-
macokinetics models, which should be validated in the
context of prospective RCTs to properly tailor the doses
(and the systemic exposure) to the right intensity of GvHD
prophylaxis according to all the factors known to affect
prognosis (such as disease, phase, age, HSC sources, and
HLA mismatch), in order to counteract the potential nega-
tive effects (relapses, infections, and delayed immune
reconstitution). The use of pharmacokinetic parameters and
the ALC, already performed in retrospective analyses
[58, 59] and in a post hoc analysis of a RCT [16], deserve
further evidences, possibly in a context of large prospective
RCTs, for both ATG and ATLG.
The weaker recommendation issued by the Panel
(Table 2) in patients transplanted with an HLA-identical
donor mainly derives from a limited evidence available.
Only one trial [17] has been carried out and showed the
efficacy of ATLG. Even if ATG/ATLG administration
was not associated with survival gain, the profound
reduction of severe cGvHD significantly enhanced quality
of life [80], a fact which cannot be ignored in the patients
counseling
High uncertainty resulted in the use of ATG/ATLG in
T-cell replete haploidentical transplants when PTCy was
used, because of a lack of focused trials (Table 2). It could
be one of the most interesting setting for an RCT with the
addition or not of ATG/ATLG, in particular when in the
context of PB transplantation.
Furthermore, the Panel did not reach consensus on the
appropriateness of use of ATG/ATLG in cord blood trans-
plant (Table 2), the use of which has sensibly been
decreasing in the last years. The peculiar immunological
reconstitution after CB HSCT and the lower number of
cellular targets for ATG/ATLG (i.e., lymphocytes of the
graft) suggest targeting a lower ATG/ATLG exposure to
optimize the negative and positive effects of ATG/ATLG.
Finally, the Panel did not recommend any particular
formulation of polyclonal serum, leaving the choice to the
investigator’s discretion and personal experience. Head to
head comparison between the two brands was claimed as
the only possible way to prove overall superiority of one
of them.
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